The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
Open accessAbstract
Establishment of an in vivo small animal model of human tumor and human immune system interaction would enable preclinical investigations into the mechanisms underlying cancer immunotherapy. To this end, nonobese diabetic ( NOD).Cg‐Prkdc scid IL2rg tm1Wjl /Sz (null; NSG) mice were transplanted with human (h)CD34 + hematopoietic progenitor and stem cells, which leads to the development of human hematopoietic and immune systems [humanized NSG (HuNSG)]. HuNSG mice received human leukocyte antigen partially matched tumor implants from patient‐ derived xenografts [PDX; non ‐ small cell lung cancer (NSCLC), sarcoma, bladder cancer, and triple‐negative breast cancer (TNBC)] or from a TNBC cell line‐derived xenograft (CDX). Tumor growth curves were similar in HuNSG compared with nonhuman immune‐engrafted NSG mice. Treatment with pembrolizumab, which targets programmed cell death protein 1, produced significant growth inhibition in both CDX and PDX tumors in HuNSG but not in NSG mice. Finally, inhibition of tumor growth was dependent on hCD8 + T cells, as demonstrated by antibody‐mediated depletion. Thus, tumor‐bearing HuNSG mice may represent an important, new model for preclinical immunotherapy research.—Wang, M., Yao, L.‐C., Cheng, M., Cai, D., Martinek, J., Pan, C.‐X., Shi, W., Ma, A.‐H., De Vere White, R. W., Airhart, S., Liu, E. T., Banchereau, J., Brehm, M. A., Greiner, D. L., Shultz, L. D., Palucka, K., Keck, J. G. Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy. FASEB J. 32,1537 ‐1549 (2018). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Self-citationPredictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Humanized mice for immune system investigation: progress, promise and challenges
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3311 · Cited by 979
Self-citationDevelopment of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 932
Self-citationThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Development and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789
Translation of Research Evidence From Animals to Humans
Hackam, D. G., & Redelmeier, D. A. (2006) · JAMA · doi:10.1001/jama.296.14.1731 · Cited by 733
Humanized Mouse Models of Clinical Disease
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K.-E., Greiner, D. L., Brehm, M. A., & Shultz, L. D. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100332 · Cited by 562
Self-citationTargeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund-Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 445
Gerner, M. Y., Kastenmuller, W., Ifrim, I., Kabat, J., & Germain, R. N. (2012) · Immunity · doi:10.1016/j.immuni.2012.07.011 · Cited by 425
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405 · cited 1×
“The inconsistency between our data and the clinical data (48), in terms of intratumoral CD8 T-cell infiltrates, could be a result of inefficient human lymphocyte trafficking to the tumor, aswell as the dampened dendritic”
Shultz, L. D., Saito, Y., Najima, Y., Tanaka, S., Ochi, T., Tomizawa, M., Doi, T., Sone, A., Suzuki, N., Fujiwara, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000475107 · Cited by 366
Self-citationStrowig, T., Gurer, C., Ploss, A., Liu, Y.-F., Arrey, F., Sashihara, J., Koo, G., Rice, C. M., Young, J. W., Chadburn, A., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081720 · Cited by 300
Rosenblatt, J., Glotzbecker, B., Mills, H., Vasir, B., Tzachanis, D., Levine, J. D., Joyce, R. M., Wellenstein, K., Keefe, W., Schickler, M., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821ca6ce · Cited by 283
Chen, Q., Khoury, M., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912274106 · Cited by 271
Specificity of T-cell alloreactivity
Felix, N. J., & Allen, P. M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2200 · Cited by 254
Merryman, R. W., Kim, H. T., Zinzani, P. L., Carlo-Stella, C., Ansell, S. M., Perales, M.-A., Avigdor, A., Halwani, A. S., Houot, R., Marchand, T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738385 · Cited by 240
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
Humanized hemato-lymphoid system mice
Theocharides, A. P. A., Rongvaux, A., Fritsch, K., Flavell, R. A., & Manz, M. G. (2016) · Haematologica · doi:10.3324/haematol.2014.115212 · Cited by 166
Tanaka, S., Saito, Y., Kunisawa, J., Kurashima, Y., Wake, T., Suzuki, N., Shultz, L. D., Kiyono, H., & Ishikawa, F. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103660 · Cited by 129
Self-citationAshizawa, T., Iizuka, A., Nonomura, C., Kondou, R., Maeda, C., Miyata, H., Sugino, T., Mitsuya, K., Hayashi, N., Nakasu, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0122 · Cited by 107
Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients
Waldron-Lynch, F., Henegariu, O., Deng, S., Preston‐Hurlburt, P., Tooley, J., Flavell, R. A., & Herold, K. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003401 · Cited by 98
A novel Flt3‐deficient HIS mouse model with selective enhancement of human DC development
Li, Y., Mention, J., Court, N., Masse‐Ranson, G., Toubert, A., Spits, H., Legrand, N., Corcuff, E., Strick‐Marchand, H., & Santo, J. P. D. (2016) · European Journal of Immunology · doi:10.1002/eji.201546132 · Cited by 84
New checkpoint inhibitors ride the immunotherapy tsunami
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4066 · Cited by 74
Brehm, M., Bortell, R., Diiorio, P., Leif, J., Laning, J., Cuthbert, A., Yang, C.-X., Herlihy, M., Burzenski, L., Gott, B., et al. (2010) · Diabetes · doi:10.2337/db10-0323 · Cited by 74
Self-citationHuman dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors
Palucka, A. K., Gatlin, J., Blanck, J. P., Melkus, M. W., Clayton, S., Ueno, H., Kraus, E., Cravens, P. D., Bennett, L. B., Padgett‐Thomas, A., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0384 · Cited by 61
Self-citationMcGee, H. S., Yagita∥, H., Shao, Z., & Agrawal, D. K. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0258oc · Cited by 53
Zilberberg, J., Feinman, R., & Korngold, R. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.001 · Cited by 41
Lee, J., Dykstra, B. J., Spencer, J. A., Kenney, L. L., Greiner, D. L., Shultz, L. D., Brehm, M. A., Lin, C. P., Sackstein, R., & Rossi, D. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92030 · Cited by 28
Self-citation
Cited by
Glioma progression is shaped by genetic evolution and microenvironment interactions
Varn, F. S., Johnson, K. C., Martinek, J., Huse, J. T., Nasrallah, M. P., Wesseling, P., Cooper, L. A. D., Malta, T. M., Wade, T. E., Sabedot, T. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.038 · Cited by 494
Self-citationMouse Models for Cancer Immunotherapy Research
Olson, B., Li, Y., Lin, Y., Liu, E. T., & Patnaik, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0044 · Cited by 435
Self-citationHumanized mouse models for immuno-oncology research
Chuprin, J., Buettner, H., Seedhom, M. O., Greiner, D. L., Keck, J. G., Ishikawa, F., Shultz, L. D., & Brehm, M. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00721-2 · Cited by 423
Self-citationGuillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C.-H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00337-6 · Cited by 416
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Metadata
- Authors
- Wang, M., Yao, L., Cheng, M., Cai, D., Martinek, J., Pan, C., Shi, W., Ma, A., de Vere White, R. W., Airhart, S., Liu, E. T., Banchereau, J., Brehm, M. A., Greiner, D. L., Shultz, L. D., Palucka, K., & Keck, J. G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2018-01-03
- Volume
- 32
- Issue
- 3
- Pages
- 1537-1549
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2768987490
- Cited by
- 339
- References
- 52
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.